ENSC实时信号 | 通过Getagraph.com最大化利润

购买 107434 min ago

@ $0.897

发出时间: 15 Feb 2024 @ 04:28

回报率: -34.84%

上一信号: Feb 14 - 23:42

上一信号: 出售

回报率: -0.39 %

Live Chart Being Loaded With Signals

Commentary (27 Apr 2024 @ 04:00):

Stats
今日成交量	176 491
平均成交量	540 200
市值	4.28M
EPS	$0 ( 2024-04-04 )
下一个收益日期	( $0 ) 2024-05-13
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.120
ATR14	$0.0100 (1.71%)

Insider Trading

Date	Person	Action	Amount	type
2023-03-02	Gower Bob G	Buy	90 287	Common Stock
2023-03-01	Gower Bob G	Buy	270 000	Common Stock
2023-02-28	Gower Bob G	Buy	109 300	Common Stock
2022-12-09	Gower Bob G	Buy	357 143	Common Stock
2022-12-09	Gower Bob G	Buy	714 286	Warrants

INSIDER POWER
99.26
Last 80 transactions
Buy: 23 095 136 \| Sell: 3 675 006

音量相关性

長: 0.13 (neutral)

短: 0.26 (neutral)

Signal:(46.493) Neutral

Ensysce Biosciences, Inc. 相关性

10 最正相关
SVAC	0.928
PAIC	0.905
PRVB	0.904
SVOK	0.878
ALR	0.862
TLGT	0.852
ALLR	0.847
LKCO	0.844
RDHL	0.843
ELEV	0.839

10 最负相关
NETE	-0.92
LWAC	-0.92
MDRRP	-0.916
SRAC	-0.904
WSBCP	-0.895
RAVN	-0.889
HNST	-0.889
OVBC	-0.886
MRBK	-0.885
MNSBP	-0.883

你知道吗？

相关性是描述两个变量之间关系的统计指标。它的取值范围为-1到1，其中-1表示完全负相关（一个变量增加，另一个变量减少），1表示完全正相关（一个变量增加，另一个变量也增加），0表示没有相关性（变量之间没有关系）。

相关性可用于分析任何两个变量之间的关系，而不仅仅是股票。它通常用于金融、经济学、心理学等领域。

Ensysce Biosciences, Inc. 相关性 - 货币/商品

0.36
( neutral )

0.62
( weak )

0.00
( neutral )

-0.15
( neutral )

0.33
( neutral )

Ensysce Biosciences, Inc. 财务报表

Annual	2023
营收:	$2.23M
毛利润:	$-5.36M (-240.17 %)
EPS:	$-4.69

FY	2023
营收:	$2.23M
毛利润:	$-5.36M (-240.17 %)
EPS:	$-4.69

FY	2022
营收:	$2.52M
毛利润:	$-17.31M (-686.08 %)
EPS:	$-138.73

FY	2021
营收:	$0.00
毛利润:	$0.00 (0.00 %)
EPS:	$-29.60

Financial Reports:

No articles found.

Ensysce Biosciences, Inc.

Ensysce Biosciences, Inc., a clinical-stage pharmaceutical company, engages in developing various prescription drugs for severe pain relief in opioid addiction, misuse, abuse, and overdose in the United States. It develops products using Trypsin Activated Abuse Protection platform, an abuse-resistant opioid prodrug technology; and Multi-Pill Abuse Resistance platform, an over-dose protection opioid prodrug technology. The company is developing PF614, a TAAP prodrug candidate of oxycodone, which is in Phase II clinical trial for the treatment of acute or chronic pain; and PF614-MPAR, a combination product of PF614 and nafamostat that is in Phase I clinical trial for overdose protection against excessive oral ingestion, as well as an oral and inhalation drug product of nafamostat for use against coronaviral infections and other pulmonary diseases, such as cystic fibrosis. It is also developing PF329, an extended-release prodrug of hydromorphone that is similar to PF614; PF8001 and PF8026 are extended and immediate-release prodrugs of amphetamine for ADHD medication abuse; and PF26810, an extended-release prodrug of methadone for opioid use disorder. The company is based in La Jolla, California.